SlideShare ist ein Scribd-Unternehmen logo
1 von 105
Downloaden Sie, um offline zu lesen
GERD
Gastroesophageal Reflux Disease 
GERD 
By 
Ahmed Abudeif Abd Elaal 
Resident in tropical medicine & gastroenterology department 
2009
:Definitions 
Gastroesophageal Reflux (GER): Escape of gastric 
contents into the esophagus. This process may or may 
not produce symptoms. 
Reflux esophagitis: Esophageal inflammation caused 
by the refluxed material. 
Gastroesophageal Reflux Disease (GERD): Any 
symptomatic condition or anatomic alteration caused by 
the reflux of noxious material from the stomach into the 
esophagus.
Pathogenesis of GERD
Pathogenesis of GERD: 
A)Antireflux mechanisms. 
B) Gastric Factors. 
C) Esophageal Clearance Mechanisms. 
D) Esophageal Epithelial Resistance.
A) Antireflux Mechanisms: 
Normally, there is a positive pressure gradient 
between the abdomen and the thorax that tends to 
promote the reflux of material from the stomach into 
the esophagus. In the absence of effective antireflux 
mechanisms this pressure differential would result in 
continuous gastroesophageal reflux.
1) Lower Esophageal Sphincter (LES) 
It is a 1-3.5 cm segment of specialized circular 
muscle in the wall of distal esophagus. 
It maintains a resting pressure of 10-45 mmHg 
higher than that of the stomach.
Types of LES dysfunction: 
1) Intrinsic weakness of the LES muscle: 
The resting pressure in the LES remains at or near 0. 
Responsible for > 25% of reflux episodes in patients 
with severe GERD. 
2) Inadequate LES response to increased abdominal 
pressure.
3) Transient LES relaxation (TLESR): 
Normally, the LES relaxes for 3-10 seconds to allow 
the swallowed bolus to enter the stomach. 
TLESR is not preceded by swallowing & lasts for up 
to 45 seconds. 
It is responsible for 70% of reflux episodes in patients 
with severe GERD. 
Incompetent LES
2) Crural Diaphragm 
When the crural diaphragm contract e.g. inspiration 
the crurae come together & pinch the distal 
esophagus.
3) Anatomic Features: 
a) The oblique angle of insertion of the esophagus into 
the stomach (angle of His).
b) The circular muscle fibers of the fundus encircle 
the lower end of the esophagus. 
c) The presence of an intraabdominal segment of the 
esophagus. 
d) The mucosal rosette of the upper end of the 
stomach forming a plug to the lower end of the 
esophagus.
B) Gastric Factors: 
1) Irritant potency of the refluxed material 
Esophageal injury occurs when the refluxed material 
is caustic to the esophageal mucosa. 
Caustic agents that can be found in the stomach 
include acid, pepsin, bile & pancreatic enzymes.
2) Delayed gastric emptying 
It causes gastric distention that can stimulate 
gastric acid secretion & trigger TLESR. 
Causes: 
1- Pyloric channel or duodenal ulcers. 
2- Mechanical obstruction e.g. by tumour. 
3- Neuromuscular abnormalities e.g. DM, 
collagen diseases, hypothyroidism, …
C) Esophageal Clearance Mechanisms: 
The esophagus is cleared of acid by 4 mechanisms: 
1)Gravity. 
2) Peristalsis. 
3) Salivation. 
4) Intrinsic esophageal bicarbonate production.
Impaired esophageal clearance can occur in: 
Sleep: due to 
1) Elimination of the effect of gravity. 
2) Salivation & swallowing cease during sleep 
“no peristalsis due to absent swallowing”. 
Scleroderma: due to impaired peristalsis. 
Cigarette smoking: due to decreased salivation. 
Hiatus hernia.
D) Esophageal Epithelial Resistance: 
a) Pre-epithelial defenses: 
1) Mucous layer: 
Acts as a lubricant & a protective barrier against 
noxious &irritant luminal contents. 
2) Unstirred water layer: 
Lies under the mucous layer & its rich in 
bicarbonate. 
It provides a protective alkaline microenvironment. 
b) Post-epithelial defenses.
Diagnosis of GERD
A) Clinical Presentation 
1) Heartburn (Pyrosis): 
Substernal burning sensation radiating to the chest 
sometimes to the throat or the back. 
The pain is usually relieved by ingestion of 
antacids. within 5 minutes 
The pain is aggravated by 
- Ingestion of foods that decrease the LES 
pressure as chocolate, onions, peppermint, coffee, 
tea & foods that have a high content of fat & sugar.
- Ingestion of foods that irritate the esophageal 
mucosa directly as spicy foods, citrus products 
and tomato products. 
- Practices that increase the intraabdominal 
pressure e.g. bend over, lift a heavy object, 
strain to defecate or run.
2) Regurgitation: 
Reflux of sour or bitter material into the mouth 
usually at night, when lying down or bending over. 
It suggests severe reflux.
3) Dysphagia: 
Difficulty in swallowing. 
Usually indicates narrowing or stricture of the 
esophagus. 
It may occur due to inflammation & oedema.
4) Odynophagia: 
Pain on swallowing. 
It suggests the presence of esophageal 
ulceration.
5) Water brash: 
Filling of the mouth suddenly with saliva. 
Its due to reflex salivary secretion stimulated by 
acid in the esophagus.
6) Chest pain: 
Resembles anginal pain. 
This pain may result from: 
• Acid induced irritation of the nerve endings. 
• GER-induced esophageal spasm. 
• GER-induced angina pectoris.
7) Haemorrhage
8) Pulmonary symptoms: 
e.g. chronic cough, hoarseness of voice, 
wheezing, haemoptysis, asthma & recurrent 
aspiration pneumonia. 
The above manifestations may be due to 
aspiration or vagus mediated neural reflexes.
9) Nighttime GER may cause: 
Sleep apnoea. 
Poor sleep. 
Insomnia. 
Daytime sleepiness.
B) Diagnostic tests: 
Indications: 
1) Patients with atypical signs or 
symptoms. 
2) Patients with typical signs & 
symptoms that don’t respond well to 
acid suppression.
1) Endoscopic examination: 
EGD identifies the presence and severity of 
esophagitis and the possible presence of 
Barrett’s esophagus 
More sensitive than radiology for diagnosis of 
esophagitis & biopsy can be taken from any 
abnormal areas. 
Endoscopic evidence of esophagitis is present in 
50-70% of patients with typical history of GERD 
so a normal EGD (NERD) doesn’t exclude 
GERD.
TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc 
aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss 
GGrraaddee DDeessccrriippttiioonn 
AA One or more mucosal breaks no longer than 5 mm, none 
of which extends between the tops of the mucosal folds. 
BB One or more mucosal breaks more than 5 mm long, none 
of which extends between the tops of two mucosal folds. 
CC Mucosal breaks that extend between the tops of two or 
more mucosal folds, but which involve less than 75% of 
the esophageal circumference. 
DD Mucosal breaks which involve at least 75% of the 
esophageal circumference.
The Los Angeles Classification SSyysstteemm ffoorr tthhee eennddoossccooppiicc 
aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss
The Los Angeles Classification SSyysstteemm ffoorr tthhee eennddoossccooppiicc 
aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss 
GRADE A: 
One or more mucosal breaks no 
longer than 5 mm, non of which 
extends between the tops of 
the mucosal folds
TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc 
aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss 
GGRRAADDEE BB:: 
OOnnee oorr mmoorree mmuuccoossaall 
bbrreeaakkss mmoorree tthhaann 55 mmmm 
lloonngg,, nnoonnee ooff wwhhiicchh 
eexxtteennddss bbeettwweeeenn tthhee 
ttooppss ooff ttwwoo mmuuccoossaall ffoollddss
TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc 
aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss 
GGRRAADDEE CC:: 
MMuuccoossaall bbrreeaakkss tthhaatt eexxtteenndd 
bbeettwweeeenn tthhee ttooppss ooff ttwwoo oorr 
mmoorree mmuuccoossaall ffoollddss,, bbuutt wwhhiicchh 
iinnvvoollvvee lleessss tthhaann 7755%% ooff tthhee 
ooeessoopphhaaggeeaall cciirrccuummffeerreennccee
TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc 
aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss 
GGRRAADDEE DD:: 
MMuuccoossaall bbrreeaakkss wwhhiicchh 
iinnvvoollvvee aatt lleeaasstt 7755%% ooff 
tthhee ooeessoopphhaaggeeaall 
cciirrccuummffeerreennccee
Savary-Miller Classification of esophagitis 
Grade I: Single or multiple erosions are found on a single 
fold; erosions may be erythematous or exudative.
Savary-Miller Classification of esophagitis 
Grade II: Multiple erosions affect multiple folds.
Savary-Miller Classification of esophagitis 
Grade III: Multiple circumferential erosions.
Savary-Miller Classification of esophagitis 
Grade IV: Ulcer, stricture, and esophageal shortening.
Savary-Miller Classification of esophagitis 
Grade V: Barrett’s epithelium.
2) Barium swallow: 
Can reveal: 
a)Signs of esophagitis including: 
1- Thickening of the esophageal folds. 
2- Erosions. 
3- Ulcerations. 
4- Strictures. 
b) GER of barium.
Disadvantages: 
1) Less sensitive than endoscopy for 
demonstrating esophagitis. 
2) Biopsy specimens can't be taken.
3) Ambulatory monitoring of esophageal pH: 
Its used to document the pattern, frequency & 
duration of acid reflux & to seek correlation between 
reflux episodes & symptoms. 
Normally, esophageal pH remains below 4 for less 
than 4.5% of the 24-hour monitoring period. 
Acid reflux episode: a drop in esophageal pH 
below 4 & the total Reflux episodes exceed 5% of 
the total monitoring time.
4) Acid perfusion (Bernstein) test: 
It has been used to support acid reflux as the 
cause of symptoms. 
The esophagus is perfused with 0.1 N HCl. 
Reproduction of chest pain with acid perfusion 
implicates GERD as a cause of chest pain.
5) Histology: 
Histological changes of esophagitis: 
1) Lengthening of the papillae so that they occupy 
more than 2/3 of the thickness of the squamous 
mucosa. 
2) Hyperplasia of cells in the basal zone so that it 
occupies more than 15% of the mucosal 
thickness. 
3) Infiltration of the epithelium with eosinophils & 
PMNLs.
Treatment of GERD
A)Medical Treatment: 
a) Lifestyle Modifications. 
b) Pharmacologic Therapy: 
1) H2 blockers 
2) Proton Pump Inhibitors. 
3) Antacids. 
4) Prokinetic Drugs. 
5) Sucralfate. 
B) Antireflux Surgery. 
C) Endoscopic Antireflux Procedures.
A)Medical Treatment: 
a) Lifestyle Modifications: 
1) Elevation of the head of the bed by 4-6 inch 
blocks or 6 inch foam-rubber wedge in place of 
or under the pillow. 
2) Weight loss for obese patients. 
- Obesity increase the intraabdominal pressure.
3) Avoid: 
a) Smoking 
- It decrease LES pressure & salivation. 
b) Alcohol 
- It decrease LES pressure. 
c) Fatty meal, chocolate, onion, tea, coffee & 
carminatives. 
- They decrease LES pressure & delay gastric 
emptying.
d) Spicy foods, citrus & tomato products. 
- They cause direct irritation of the esophageal 
mucosa. 
e) Drugs that decrease LES pressure & delay 
gastric emptying as Ca++ channel blockers, 
nitrates, drugs that have anticholinergic effects 
“e.g. phenothiazines, TCA”, theophylline 
preparations, progesterone & benzodiazepines.
4) Encourage small frequent meals, the evening 
meal should be light & easy to digest. 
5) No eating 3 hours prior to sleep. 
- Bed time snacks stimulate gastric acid secretion 
& trigger TLESR.
b) Pharmacologic Therapy: 
1) H2 Blockers: 
These drugs block the effect of histamine on H2 
receptors which is present normally in gastric 
mucosa, vascular smooth muscle & the heart. 
They reduce the basal, food stimulated & 
nocturnal secretion of gastric HCl. 
Usually effective in controlling symptoms of mild 
to moderate GER & heal esophagitis (grade I,II) 
within 12 weeks in about ½ to 2/3 of patients.
Drug Indication Dose Duration 
Cimetidine - Erosive esophagitis diagnosed 
by endoscopy. 
- 800 mg BDS 
or 400 mg 
QDS 
- 12 w 
Famotidine - Short term ttt of symptoms. 
- Esophagitis due to GERD 
including erosive or ulcerative 
disease diagnosed by endoscopy 
- 20 mg BDS 
- 20-40 mg 
BDS 
-6 w 
- 12 w 
Nizatidine - Esophagitis due to GERD. 
including erosive or ulcerative 
disease & associated heartburn. 
- 150 mg BDS - 12 w 
Ranitidine - Treatment of symptoms. 
- Esophagitis due to GERD 
including erosive or ulcerative 
disease diagnosed by endoscopy 
-150 mg BDS 
- 150 mg QDS 
No 
limit 
specifi 
ed
2) Proton Pump Inhibitors (PPIs): 
These drugs inhibit parietal cell proton pump (H+ 
K+ - ATPase). 
Proton pump is responsible for extrusion of H+ 
into the gastric lumen in exchange of K+ which is 
the final step in gastric acid production. 
PPIs are effective in control of symptoms & signs 
of GERD, heal erosive esophagitis & diminish 
formation of esophageal strictures. 
PPIs improves dysphagia & decrease the need 
for esophageal dilatation in patients who have 
esophageal strictures.
PPIs are effective if taken 15-30 minutes before 
breakfast or dinner. 
Drugs of this group include: 
- Omeprazole 20 mg - 40 mg. 
- Lansoprazole 15 mg – 30 mg. 
- Rapeprazole 20 mg. 
- Pantoprazole 20 mg – 40 mg. 
- Esomeprazole 20 mg – 40 mg. 
- Omeprazole NaHCO3 20 mg – 40 mg.
Side effects of PPIs: 
- Headache, nausea & vomiting. 
- Diarrhoea & Clostridium difficile colitis. 
- Theoretically, they may cause gastric bacterial 
overgrowth, vitamin B12 & iron malabsorption & 
gastric cancer. However, there is no clinical 
support. 
- Hypocalcaemia (give Ca++ supplements as Ca++ 
citrate).
3) Antacids: 
Antacids may be aluminum, magnesium, or 
calcium based 
Antacids neutralize the acid in the stomach so 
that there is no acid to reflux. 
Antacids emptied from the empty stomach 
quickly so they should be given an hour after 
meal to prolong their duration of action. 
Effective in controlling mild symptoms of GERD.
4) Prokinetic Drugs: 
These agents act by: 
a) Increasing LES pressure. 
b) Enhancing gastric & esophageal emptying. 
Examples: 
1) Metoclopramide HCl. 
2) Domperidone. 
3) Mosapride citrate.
1) Metoclopramide HCl: 
- Dopamine antagonist, centrally acting 
antiemetic. 
- Its effective in treatment of mild disease. 
- It crosses BBB so, it has many central side 
effects. 
Side effects: 
Agitation, restlessness, somnolence, anxiety, 
insomnia, extrapyramidal manifestations & 
galactorrhoea.
2) Domperidone: 
- Dopamine antagonist & produce effects similar 
to metoclopramide. 
- Unlike metoclopramide it doesn’t cross BBB so 
there is no central side effects.
3) Mosapride citrate: 
- 5-HT4 receptor agonist & partial 5-HT3 
antagonist. 
- Unlike cisapride it doesn’t block K+ channels so 
no cardiac toxicity will occur, also doesn’t block 
D2 receptors, so there is no extrapyramidal 
manifestations.
5) Sucralfate: 
- An aluminum sucrose polysulfate. 
- Effective in treatment of mild reflux esophagitis. 
- It is efficacy is comparable to that of H2 blockers.
B) Antireflux Surgery: 
There are a number of different antireflux 
operations (e.g. Nissen, Belesy, Toupet 
fundoplication). 
The most popular is Nissen fundoplication (open 
or laparoscopic). 
Nissen fundoplication
Principle of antireflux surgery: 
The surgeon 
1) Creates an intraabdominal segment of 
esophagus. 
2) Reduces the hiatal hernia. 
3) Approximates the diaphragmatic crurae. 
4) Wraps a portion of gastric fundus around the 
distal esophagus.
- There is relief of symptoms & signs in > 85% of 
patients. 
- Antireflux surgery was associated with a significant 
decrease in long term survival so it should be 
restricted to: 
1) Patients who no longer need to take 
antisecretory medications. 
2) The procedure will prevent esophageal cancer
C) Endoscopic Antireflux Procedures: 
The Bard endoscopic suturing system: 
This system uses an endoscopic sewing machine 
device to plicate the esophagogastric junction from 
the mucosal side. 
The Stretta system: 
The Stretta system delivers radiofrequency energy 
that creates thermal lesions in the LES muscle. 
Injection of collagen circumferentially at the LES.
Complications of GERD
1) Esophageal Stricture: 
Peptic strictures form when reflux induced ulceration 
stimulates fibrous tissue production & collagen 
deposition in the esophagus. 
Up to 11% of patients with GERD seem to develop 
strictures.
Factors predisposing to stricture formation: 
- Prolonged GER. 
- Reflux while supine. 
- Nasogastric intubation. 
- Duodenal ulcer disease. 
- Gastric hypersecretory states. 
- Postgastrectomy states. 
- Scleroderma. 
- Treated achalasia.
Site of esophageal stricture: 
- Usually in the distal 1/3 of the esophagus. 
- In some cases of Barrett’s esophagus the stricture 
is located in the middle or less commonly in the 
proximal 1/3 of the esophagus.
Clinical Picture: 
- Esophageal stricture produce no symptoms until 
the esophageal intraluminal diameter < 12 mm. 
- Typically there is a slowly progressive dysphagia 
initially for solids & later on for liquids. 
- Profound weight loss is uncommon.
Investigations: 
a)Barium Swallow: 
- Peptic strictures have a smooth tapered 
appearance. 
- More sensitive than endoscopy for demonstrating 
subtle esophageal narrowing. 
b) Endoscopy: 
- Endoscopic examination with biopsy & brush 
cytology of the esophagus is necessary to exclude 
cancer.
Treatment: 
- Intensive medical treatment with PPIs both 
improves dysphagia & decreases the need for 
esophageal dilatation. 
- Progressive dilatation with: 
• Mercury filled rubber bougies. 
• Savary-Gillard dilators. 
• Balloons that can be inflated within the stricture.
- Surgical treatment, usually combined with an 
antireflux operation. 
- Resection with esophageal reconstruction using a 
segment of bowel in cases of intractable stricture.
B) Barrett’s Esophagus: 
- A condition in which a metaplastic columnar 
epithelium replaces squamous epithelium in the 
distal esophagus. 
- Barrett’s esophagus is a strong risk factor for 
adenocarcinoma of the esophagus & 
gastroesophageal junction.
- It is usually discovered in middle aged & older 
adults. However its found in children as young as 5 
years. 
- Barrett’s esophagus predominates in white 
males. Its uncommon in blacks & asians.
Histology: 
Any of 3 types of columnar epithelia can be found 
in Barrett’s esophagus. 
1) Gastric fundic type epithelium. 
2) Junctional type epithelium. 
3) Specialized intestinal metaplasia “Specialized 
columnar epithelium”. 
- Dysplasia & carcinoma are associated with 
intestinal metaplasia.
Diagnosis 
Clinical Picture: 
- The Barrett’s epithelium causes no symptoms. 
- Most patients have symptoms of GERD, the 
GERD associated with Barrett’s esophagus often is 
severe & associated with esophageal ulceration, 
stricture & haemorrhage. However, many patients 
have no symptoms of GERD. 
- Cancer risk is about 0.5% annually.
Endoscopy: 
- Columnar epithelium can be recognized by it’s 
characteristic red colour & velvet like texture that 
contrast sharply with the pale glossy appearance of 
the adjacent squamous epithelium. 
- According to the length of the lining columnar 
epithelium Barrett’s esophagus can be classified 
into: 
- Short segment Barrett’s esophagus: intestinal 
metaplasia lines < 3 cm of the distal esophagus.
- Long segment Barrett’s esophagus: intestinal 
metaplasia lines > 3 cm of the distal esophagus. 
- Long segment Barrett’s esophagus is associated 
with high risk for developing adenocarcinoma.
Management 
• Patients with Barrett’s esophagus should 
undergo surveillance endoscopy & biopsy at an 
interval determined by the presence & grade of 
dysplasia: 
• For patients with no dysplasia, surveillance 
endoscopy is recommended at an interval of every 
2-3 years.
• For patients with low grade dysplasia, 
surveillance endoscopy every 6 months for the 1st 
year is recommended, followed by yearly 
endoscopy if the dysplasia hasn’t progressed in 
severity. 
• For patients with high grade dysplasia 2 options 
are available: 
1) Intensive endoscopic surveillance until 
intramucosal cancer is detected. 
2) Esophageal resection.
- GERD should be treated aggressively prior to 
surveillance endoscopy to minimize confusion 
caused by inflammation in the interpretation of 
biopsy specimens.
Refractory GERD
Refractory GERD: patients who continue to have 
symptoms of gastroesophageal reflux despite 
standard treatment with proton pump inhibitors 
(PPIs). 
Patients who experience refractory GERD 
usually fall into one of two groups: 
- Those who need more aggressive treatment 
- Those who have other causes of their reflux 
symptoms
1) Inadequate response to PPIs
Factors contributing to inadequate PPI 
response: 
1) Nocturnal Acid Breakthrough (NAB) 
2) Reduced bioavailability 
3) Effect of food and dosing interval 
4) Differences in metabolism 
5) Gastric acid hypersecretion 
6) Helicobacter pylori status 
7) Drug resistance, slow healing
Nocturnal Acid Breakthrough (NAB) 
Nocturnal acid exposure while on PPI. 
Responsible for majority of patients with refractory 
GERD. 
May be reduced by H2 blockers and by increasing 
PPI dose. 
Sometimes difficult to eliminate.
Reduced Bioavailability 
Bioavailability of PPI influenced by environmental 
and manufacturing conditions. 
For most patients, difference in bioavailability are not 
clinically significant.
Effect of food and dosing interval 
Administration 15-30 min prior to meals improve 
gastric acid suppression. 
PPI usually given once daily and sometimes twice 
daily improve gastric acid suppression.
Differences in metabolism 
PPI metabolized through the CYP 2C. 
CYP 2C absent: 
- 3% of Caucasian patients. 
- In more than 10% in Asians.
Gastric acid hypersecretion 
Patients with BAO > 10mEq/h may predisposed 
to refractory GERD.
Helicobacter pylori status 
Role not established in refractory patients. 
Helicobacter pylori infection may protect the 
esophagus from GERD & its complications 
perhaps by decreasing gastric acidity. 
No evidence that eradication exacerbates GERD.
Drug Resistance 
Resistance is a rare condition caused by mutations 
of the proton pump. 
Patients can be treated by H2 blockers.
2) Other causes of reflux 
symptoms
Other Causes Of Reflux Symptoms: 
1) Other pathological situations. 
2) Esophageal hypersensitivity. 
3) Non acid reflux.
Other Pathological Situation 
1) IBS and dyspepsia with overlap syndrome. 
2) Atypical GERD (cough, asthma, NCCP). 
3) Achalasia. 
4) Cancer or stricture. 
5) Caustic and Infectious esophagitis. 
6) NSAID (more susceptibility to acid related E 
disease).
Esophageal Hypersensitivity 
There is hypersensitivity to physiologic acid reflux 
(visceral hyperalgesia). 
Patients have heartburn but without endoscopic or 
pH evidence of GERD. 
Treatment: 
Acid suppressive therapy and low dose 
antidepressants
Non Acid Reflux 
Mixed acid and bile refluxate (more aggressive than 
acid alone). 
Duodenogastroesophageal reflux (DGER): in 
patients with gastric surgery.
Treatment of Refractory GERD
Medical treatment 
-Give PPI twice daily. 
-PPI dose before dinner may reduce NAB. 
-PPI 15-30 min before meals. 
- Stepwise increase dose of PPI to achieve 
adequate acid suppression (an increase in dose of 
Omeprazole to 80 mg/ day→ significant decrease 
in acid secretion (Vs 20 mg bid) (pH <4: 33% Vs 
74%).
- Addition of a nighttime dose H2 blockers to control 
NAB. 
- H2 blockers not as effective as PPI for maintenance 
therapy. 
- Switching to another PPI for patients refractory to 
one PPI ( rare mutations in the PP induce 
resistance). 
- Effectiveness of adding prokinetic drug not 
established.
- Add Baclofen (GABA-B agonist ): 
• Effective to treat GERD with chronic cough. 
• Inhibits TLESR. 
• With Esomeprazole both decrease total acid 
and non acid reflux. 
Endoscopic treatment 
Surgical treatment
GERD

Weitere ähnliche Inhalte

Was ist angesagt?

GASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASE GASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASE Jaison Daniel
 
Gastroesophageal reflux disorder- GERD
Gastroesophageal reflux disorder- GERDGastroesophageal reflux disorder- GERD
Gastroesophageal reflux disorder- GERDSelvaraj Balasubramani
 
Peptic ulcer disease causes and treatment
Peptic ulcer disease causes and treatmentPeptic ulcer disease causes and treatment
Peptic ulcer disease causes and treatmentAbu Bakar
 
Esophageal p h studies in esophageal disease
Esophageal p h studies in esophageal disease Esophageal p h studies in esophageal disease
Esophageal p h studies in esophageal disease Andrea Naranjo
 
Irritable bowel syndrome
Irritable bowel syndromeIrritable bowel syndrome
Irritable bowel syndromewisam alsaedi
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer diseaseKavyaHB
 
peptic ulcer disease.PPT
peptic ulcer disease.PPTpeptic ulcer disease.PPT
peptic ulcer disease.PPTheba abou diab
 
PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]
PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]
PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]Heena Parveen
 
GASTROINTESTINAL REFLUX DISEASE (GERD)
GASTROINTESTINAL REFLUX DISEASE (GERD)GASTROINTESTINAL REFLUX DISEASE (GERD)
GASTROINTESTINAL REFLUX DISEASE (GERD)LORD OF DRUGS
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer diseasePratik Rahate
 
Gastroesophageal Reflux Disease Pathophysiology and Treatment
Gastroesophageal Reflux Disease Pathophysiology and TreatmentGastroesophageal Reflux Disease Pathophysiology and Treatment
Gastroesophageal Reflux Disease Pathophysiology and TreatmentGeorge S. Ferzli
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer diseaseNoor Ul Huda
 
Irritable Bowel Syndrome
Irritable Bowel SyndromeIrritable Bowel Syndrome
Irritable Bowel SyndromePV. Viji
 
GERD (Gastro Esophageal Reflux Disease)
GERD (Gastro Esophageal Reflux Disease)GERD (Gastro Esophageal Reflux Disease)
GERD (Gastro Esophageal Reflux Disease)Sanjiv Haribhakti
 

Was ist angesagt? (20)

Peptic ulcer
Peptic ulcerPeptic ulcer
Peptic ulcer
 
GASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASE GASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASE
 
Pud
PudPud
Pud
 
Gastroesophageal reflux disorder- GERD
Gastroesophageal reflux disorder- GERDGastroesophageal reflux disorder- GERD
Gastroesophageal reflux disorder- GERD
 
GERD &STRESS
GERD &STRESSGERD &STRESS
GERD &STRESS
 
Peptic ulcer disease causes and treatment
Peptic ulcer disease causes and treatmentPeptic ulcer disease causes and treatment
Peptic ulcer disease causes and treatment
 
Esophageal p h studies in esophageal disease
Esophageal p h studies in esophageal disease Esophageal p h studies in esophageal disease
Esophageal p h studies in esophageal disease
 
Irritable bowel syndrome
Irritable bowel syndromeIrritable bowel syndrome
Irritable bowel syndrome
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer disease
 
Esophagitis
Esophagitis Esophagitis
Esophagitis
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer disease
 
peptic ulcer disease.PPT
peptic ulcer disease.PPTpeptic ulcer disease.PPT
peptic ulcer disease.PPT
 
PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]
PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]
PHARMACOTHERAPY OF Gastric-oesophagal reflux disease [GERD]
 
GASTROINTESTINAL REFLUX DISEASE (GERD)
GASTROINTESTINAL REFLUX DISEASE (GERD)GASTROINTESTINAL REFLUX DISEASE (GERD)
GASTROINTESTINAL REFLUX DISEASE (GERD)
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer disease
 
Gastroesophageal Reflux Disease Pathophysiology and Treatment
Gastroesophageal Reflux Disease Pathophysiology and TreatmentGastroesophageal Reflux Disease Pathophysiology and Treatment
Gastroesophageal Reflux Disease Pathophysiology and Treatment
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer disease
 
Peptic ulcer
Peptic ulcerPeptic ulcer
Peptic ulcer
 
Irritable Bowel Syndrome
Irritable Bowel SyndromeIrritable Bowel Syndrome
Irritable Bowel Syndrome
 
GERD (Gastro Esophageal Reflux Disease)
GERD (Gastro Esophageal Reflux Disease)GERD (Gastro Esophageal Reflux Disease)
GERD (Gastro Esophageal Reflux Disease)
 

Ähnlich wie GERD

Dysphagia – non malignant causes
Dysphagia – non malignant causesDysphagia – non malignant causes
Dysphagia – non malignant causesVed Ranjan
 
Gastroesophageal reflux disease
Gastroesophageal reflux diseaseGastroesophageal reflux disease
Gastroesophageal reflux diseaseAbhinav Srivastava
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer diseaseLincyAsha
 
Lecture 16 esophagus and stomach disorders - Pathology
Lecture 16 esophagus and stomach disorders - PathologyLecture 16 esophagus and stomach disorders - Pathology
Lecture 16 esophagus and stomach disorders - PathologyAreej Abu Hanieh
 
Surgery Esophagus Tg
Surgery Esophagus TgSurgery Esophagus Tg
Surgery Esophagus TgMiami Dade
 
GERD (gastro esophageal reflux disease) and Achalasia cardia
GERD (gastro esophageal reflux disease) and Achalasia cardiaGERD (gastro esophageal reflux disease) and Achalasia cardia
GERD (gastro esophageal reflux disease) and Achalasia cardiaRishabh Handa
 
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDaydGastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDaydMatthewTennant613
 
Pud Gastritis Lecture[1]
Pud Gastritis Lecture[1]Pud Gastritis Lecture[1]
Pud Gastritis Lecture[1]Miami Dade
 
Gastro-oesophageal reflux (GORD)
Gastro-oesophageal reflux (GORD)Gastro-oesophageal reflux (GORD)
Gastro-oesophageal reflux (GORD)meducationdotnet
 
GERD / GASTRO ESOPHAGEAL REFLUX
GERD / GASTRO ESOPHAGEAL REFLUX GERD / GASTRO ESOPHAGEAL REFLUX
GERD / GASTRO ESOPHAGEAL REFLUX Arun Karmakar
 
4) PEPTIC ULCERS-Power Point-1.pptx
4) PEPTIC ULCERS-Power Point-1.pptx4) PEPTIC ULCERS-Power Point-1.pptx
4) PEPTIC ULCERS-Power Point-1.pptxmonthjanuary662
 
Seminar on esophageal function
Seminar on esophageal functionSeminar on esophageal function
Seminar on esophageal functionSoumen Kanjilal
 
Ulcers
UlcersUlcers
Ulcersankit
 
Gastro intestinal Bleeding
Gastro intestinal BleedingGastro intestinal Bleeding
Gastro intestinal Bleedingshabeel pn
 
Lect.3.diseases of esophagus
Lect.3.diseases of  esophagusLect.3.diseases of  esophagus
Lect.3.diseases of esophagusMohanad Aljashamy
 

Ähnlich wie GERD (20)

Dysphagia – non malignant causes
Dysphagia – non malignant causesDysphagia – non malignant causes
Dysphagia – non malignant causes
 
Gastroesophageal reflux disease
Gastroesophageal reflux diseaseGastroesophageal reflux disease
Gastroesophageal reflux disease
 
Au med
Au medAu med
Au med
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer disease
 
Lecture 16 esophagus and stomach disorders - Pathology
Lecture 16 esophagus and stomach disorders - PathologyLecture 16 esophagus and stomach disorders - Pathology
Lecture 16 esophagus and stomach disorders - Pathology
 
GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
 
Surgery Esophagus Tg
Surgery Esophagus TgSurgery Esophagus Tg
Surgery Esophagus Tg
 
GERD (gastro esophageal reflux disease) and Achalasia cardia
GERD (gastro esophageal reflux disease) and Achalasia cardiaGERD (gastro esophageal reflux disease) and Achalasia cardia
GERD (gastro esophageal reflux disease) and Achalasia cardia
 
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDaydGastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
 
Pud Gastritis Lecture[1]
Pud Gastritis Lecture[1]Pud Gastritis Lecture[1]
Pud Gastritis Lecture[1]
 
Gastro-oesophageal reflux (GORD)
Gastro-oesophageal reflux (GORD)Gastro-oesophageal reflux (GORD)
Gastro-oesophageal reflux (GORD)
 
Peptic ulcer
Peptic ulcerPeptic ulcer
Peptic ulcer
 
regurgitation
regurgitationregurgitation
regurgitation
 
GERD / GASTRO ESOPHAGEAL REFLUX
GERD / GASTRO ESOPHAGEAL REFLUX GERD / GASTRO ESOPHAGEAL REFLUX
GERD / GASTRO ESOPHAGEAL REFLUX
 
Peptic ulcer disease
Peptic ulcer diseasePeptic ulcer disease
Peptic ulcer disease
 
4) PEPTIC ULCERS-Power Point-1.pptx
4) PEPTIC ULCERS-Power Point-1.pptx4) PEPTIC ULCERS-Power Point-1.pptx
4) PEPTIC ULCERS-Power Point-1.pptx
 
Seminar on esophageal function
Seminar on esophageal functionSeminar on esophageal function
Seminar on esophageal function
 
Ulcers
UlcersUlcers
Ulcers
 
Gastro intestinal Bleeding
Gastro intestinal BleedingGastro intestinal Bleeding
Gastro intestinal Bleeding
 
Lect.3.diseases of esophagus
Lect.3.diseases of  esophagusLect.3.diseases of  esophagus
Lect.3.diseases of esophagus
 

Mehr von Ahmed Abudeif

Mesenteric vascular disease
Mesenteric vascular diseaseMesenteric vascular disease
Mesenteric vascular diseaseAhmed Abudeif
 
Vascular disorders of the liver
Vascular disorders of the liverVascular disorders of the liver
Vascular disorders of the liverAhmed Abudeif
 
Nutritional assessment
Nutritional assessmentNutritional assessment
Nutritional assessmentAhmed Abudeif
 
Heart and git interaction
Heart and git interactionHeart and git interaction
Heart and git interactionAhmed Abudeif
 
Liver in systemic disease
Liver in systemic diseaseLiver in systemic disease
Liver in systemic diseaseAhmed Abudeif
 
Heavy smoking & liver
Heavy smoking & liverHeavy smoking & liver
Heavy smoking & liverAhmed Abudeif
 
Autoimmune hepatitis
Autoimmune hepatitisAutoimmune hepatitis
Autoimmune hepatitisAhmed Abudeif
 
Eosinophilic meningitis
Eosinophilic meningitisEosinophilic meningitis
Eosinophilic meningitisAhmed Abudeif
 

Mehr von Ahmed Abudeif (11)

Mesenteric vascular disease
Mesenteric vascular diseaseMesenteric vascular disease
Mesenteric vascular disease
 
Vascular disorders of the liver
Vascular disorders of the liverVascular disorders of the liver
Vascular disorders of the liver
 
Nutritional assessment
Nutritional assessmentNutritional assessment
Nutritional assessment
 
Capsule endoscopy
Capsule endoscopyCapsule endoscopy
Capsule endoscopy
 
Heart and git interaction
Heart and git interactionHeart and git interaction
Heart and git interaction
 
Ulcerative colitis
Ulcerative colitisUlcerative colitis
Ulcerative colitis
 
Liver in systemic disease
Liver in systemic diseaseLiver in systemic disease
Liver in systemic disease
 
Heavy smoking & liver
Heavy smoking & liverHeavy smoking & liver
Heavy smoking & liver
 
Autoimmune hepatitis
Autoimmune hepatitisAutoimmune hepatitis
Autoimmune hepatitis
 
Eosinophilic meningitis
Eosinophilic meningitisEosinophilic meningitis
Eosinophilic meningitis
 
Ebola virus disease
Ebola virus  diseaseEbola virus  disease
Ebola virus disease
 

Kürzlich hochgeladen

High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)Mohamed Rizk Khodair
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...Ganesan Yogananthem
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 

Kürzlich hochgeladen (20)

High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 

GERD

  • 2. Gastroesophageal Reflux Disease GERD By Ahmed Abudeif Abd Elaal Resident in tropical medicine & gastroenterology department 2009
  • 3. :Definitions Gastroesophageal Reflux (GER): Escape of gastric contents into the esophagus. This process may or may not produce symptoms. Reflux esophagitis: Esophageal inflammation caused by the refluxed material. Gastroesophageal Reflux Disease (GERD): Any symptomatic condition or anatomic alteration caused by the reflux of noxious material from the stomach into the esophagus.
  • 5. Pathogenesis of GERD: A)Antireflux mechanisms. B) Gastric Factors. C) Esophageal Clearance Mechanisms. D) Esophageal Epithelial Resistance.
  • 6. A) Antireflux Mechanisms: Normally, there is a positive pressure gradient between the abdomen and the thorax that tends to promote the reflux of material from the stomach into the esophagus. In the absence of effective antireflux mechanisms this pressure differential would result in continuous gastroesophageal reflux.
  • 7. 1) Lower Esophageal Sphincter (LES) It is a 1-3.5 cm segment of specialized circular muscle in the wall of distal esophagus. It maintains a resting pressure of 10-45 mmHg higher than that of the stomach.
  • 8. Types of LES dysfunction: 1) Intrinsic weakness of the LES muscle: The resting pressure in the LES remains at or near 0. Responsible for > 25% of reflux episodes in patients with severe GERD. 2) Inadequate LES response to increased abdominal pressure.
  • 9. 3) Transient LES relaxation (TLESR): Normally, the LES relaxes for 3-10 seconds to allow the swallowed bolus to enter the stomach. TLESR is not preceded by swallowing & lasts for up to 45 seconds. It is responsible for 70% of reflux episodes in patients with severe GERD. Incompetent LES
  • 10. 2) Crural Diaphragm When the crural diaphragm contract e.g. inspiration the crurae come together & pinch the distal esophagus.
  • 11. 3) Anatomic Features: a) The oblique angle of insertion of the esophagus into the stomach (angle of His).
  • 12. b) The circular muscle fibers of the fundus encircle the lower end of the esophagus. c) The presence of an intraabdominal segment of the esophagus. d) The mucosal rosette of the upper end of the stomach forming a plug to the lower end of the esophagus.
  • 13. B) Gastric Factors: 1) Irritant potency of the refluxed material Esophageal injury occurs when the refluxed material is caustic to the esophageal mucosa. Caustic agents that can be found in the stomach include acid, pepsin, bile & pancreatic enzymes.
  • 14. 2) Delayed gastric emptying It causes gastric distention that can stimulate gastric acid secretion & trigger TLESR. Causes: 1- Pyloric channel or duodenal ulcers. 2- Mechanical obstruction e.g. by tumour. 3- Neuromuscular abnormalities e.g. DM, collagen diseases, hypothyroidism, …
  • 15. C) Esophageal Clearance Mechanisms: The esophagus is cleared of acid by 4 mechanisms: 1)Gravity. 2) Peristalsis. 3) Salivation. 4) Intrinsic esophageal bicarbonate production.
  • 16. Impaired esophageal clearance can occur in: Sleep: due to 1) Elimination of the effect of gravity. 2) Salivation & swallowing cease during sleep “no peristalsis due to absent swallowing”. Scleroderma: due to impaired peristalsis. Cigarette smoking: due to decreased salivation. Hiatus hernia.
  • 17. D) Esophageal Epithelial Resistance: a) Pre-epithelial defenses: 1) Mucous layer: Acts as a lubricant & a protective barrier against noxious &irritant luminal contents. 2) Unstirred water layer: Lies under the mucous layer & its rich in bicarbonate. It provides a protective alkaline microenvironment. b) Post-epithelial defenses.
  • 19. A) Clinical Presentation 1) Heartburn (Pyrosis): Substernal burning sensation radiating to the chest sometimes to the throat or the back. The pain is usually relieved by ingestion of antacids. within 5 minutes The pain is aggravated by - Ingestion of foods that decrease the LES pressure as chocolate, onions, peppermint, coffee, tea & foods that have a high content of fat & sugar.
  • 20. - Ingestion of foods that irritate the esophageal mucosa directly as spicy foods, citrus products and tomato products. - Practices that increase the intraabdominal pressure e.g. bend over, lift a heavy object, strain to defecate or run.
  • 21. 2) Regurgitation: Reflux of sour or bitter material into the mouth usually at night, when lying down or bending over. It suggests severe reflux.
  • 22. 3) Dysphagia: Difficulty in swallowing. Usually indicates narrowing or stricture of the esophagus. It may occur due to inflammation & oedema.
  • 23. 4) Odynophagia: Pain on swallowing. It suggests the presence of esophageal ulceration.
  • 24. 5) Water brash: Filling of the mouth suddenly with saliva. Its due to reflex salivary secretion stimulated by acid in the esophagus.
  • 25. 6) Chest pain: Resembles anginal pain. This pain may result from: • Acid induced irritation of the nerve endings. • GER-induced esophageal spasm. • GER-induced angina pectoris.
  • 27. 8) Pulmonary symptoms: e.g. chronic cough, hoarseness of voice, wheezing, haemoptysis, asthma & recurrent aspiration pneumonia. The above manifestations may be due to aspiration or vagus mediated neural reflexes.
  • 28. 9) Nighttime GER may cause: Sleep apnoea. Poor sleep. Insomnia. Daytime sleepiness.
  • 29. B) Diagnostic tests: Indications: 1) Patients with atypical signs or symptoms. 2) Patients with typical signs & symptoms that don’t respond well to acid suppression.
  • 30. 1) Endoscopic examination: EGD identifies the presence and severity of esophagitis and the possible presence of Barrett’s esophagus More sensitive than radiology for diagnosis of esophagitis & biopsy can be taken from any abnormal areas. Endoscopic evidence of esophagitis is present in 50-70% of patients with typical history of GERD so a normal EGD (NERD) doesn’t exclude GERD.
  • 31. TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss GGrraaddee DDeessccrriippttiioonn AA One or more mucosal breaks no longer than 5 mm, none of which extends between the tops of the mucosal folds. BB One or more mucosal breaks more than 5 mm long, none of which extends between the tops of two mucosal folds. CC Mucosal breaks that extend between the tops of two or more mucosal folds, but which involve less than 75% of the esophageal circumference. DD Mucosal breaks which involve at least 75% of the esophageal circumference.
  • 32. The Los Angeles Classification SSyysstteemm ffoorr tthhee eennddoossccooppiicc aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss
  • 33. The Los Angeles Classification SSyysstteemm ffoorr tthhee eennddoossccooppiicc aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss GRADE A: One or more mucosal breaks no longer than 5 mm, non of which extends between the tops of the mucosal folds
  • 34. TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss GGRRAADDEE BB:: OOnnee oorr mmoorree mmuuccoossaall bbrreeaakkss mmoorree tthhaann 55 mmmm lloonngg,, nnoonnee ooff wwhhiicchh eexxtteennddss bbeettwweeeenn tthhee ttooppss ooff ttwwoo mmuuccoossaall ffoollddss
  • 35. TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss GGRRAADDEE CC:: MMuuccoossaall bbrreeaakkss tthhaatt eexxtteenndd bbeettwweeeenn tthhee ttooppss ooff ttwwoo oorr mmoorree mmuuccoossaall ffoollddss,, bbuutt wwhhiicchh iinnvvoollvvee lleessss tthhaann 7755%% ooff tthhee ooeessoopphhaaggeeaall cciirrccuummffeerreennccee
  • 36. TThhee LLooss AAnnggeelleess CCllaassssiiffiiccaattiioonn SSyysstteemm ffoorr tthhee eennddoossccooppiicc aasssseessssmmeenntt ooff ggrraaddee ooff eessoopphhaaggiittiiss GGRRAADDEE DD:: MMuuccoossaall bbrreeaakkss wwhhiicchh iinnvvoollvvee aatt lleeaasstt 7755%% ooff tthhee ooeessoopphhaaggeeaall cciirrccuummffeerreennccee
  • 37. Savary-Miller Classification of esophagitis Grade I: Single or multiple erosions are found on a single fold; erosions may be erythematous or exudative.
  • 38. Savary-Miller Classification of esophagitis Grade II: Multiple erosions affect multiple folds.
  • 39. Savary-Miller Classification of esophagitis Grade III: Multiple circumferential erosions.
  • 40. Savary-Miller Classification of esophagitis Grade IV: Ulcer, stricture, and esophageal shortening.
  • 41. Savary-Miller Classification of esophagitis Grade V: Barrett’s epithelium.
  • 42. 2) Barium swallow: Can reveal: a)Signs of esophagitis including: 1- Thickening of the esophageal folds. 2- Erosions. 3- Ulcerations. 4- Strictures. b) GER of barium.
  • 43. Disadvantages: 1) Less sensitive than endoscopy for demonstrating esophagitis. 2) Biopsy specimens can't be taken.
  • 44. 3) Ambulatory monitoring of esophageal pH: Its used to document the pattern, frequency & duration of acid reflux & to seek correlation between reflux episodes & symptoms. Normally, esophageal pH remains below 4 for less than 4.5% of the 24-hour monitoring period. Acid reflux episode: a drop in esophageal pH below 4 & the total Reflux episodes exceed 5% of the total monitoring time.
  • 45. 4) Acid perfusion (Bernstein) test: It has been used to support acid reflux as the cause of symptoms. The esophagus is perfused with 0.1 N HCl. Reproduction of chest pain with acid perfusion implicates GERD as a cause of chest pain.
  • 46. 5) Histology: Histological changes of esophagitis: 1) Lengthening of the papillae so that they occupy more than 2/3 of the thickness of the squamous mucosa. 2) Hyperplasia of cells in the basal zone so that it occupies more than 15% of the mucosal thickness. 3) Infiltration of the epithelium with eosinophils & PMNLs.
  • 48. A)Medical Treatment: a) Lifestyle Modifications. b) Pharmacologic Therapy: 1) H2 blockers 2) Proton Pump Inhibitors. 3) Antacids. 4) Prokinetic Drugs. 5) Sucralfate. B) Antireflux Surgery. C) Endoscopic Antireflux Procedures.
  • 49. A)Medical Treatment: a) Lifestyle Modifications: 1) Elevation of the head of the bed by 4-6 inch blocks or 6 inch foam-rubber wedge in place of or under the pillow. 2) Weight loss for obese patients. - Obesity increase the intraabdominal pressure.
  • 50. 3) Avoid: a) Smoking - It decrease LES pressure & salivation. b) Alcohol - It decrease LES pressure. c) Fatty meal, chocolate, onion, tea, coffee & carminatives. - They decrease LES pressure & delay gastric emptying.
  • 51. d) Spicy foods, citrus & tomato products. - They cause direct irritation of the esophageal mucosa. e) Drugs that decrease LES pressure & delay gastric emptying as Ca++ channel blockers, nitrates, drugs that have anticholinergic effects “e.g. phenothiazines, TCA”, theophylline preparations, progesterone & benzodiazepines.
  • 52. 4) Encourage small frequent meals, the evening meal should be light & easy to digest. 5) No eating 3 hours prior to sleep. - Bed time snacks stimulate gastric acid secretion & trigger TLESR.
  • 53. b) Pharmacologic Therapy: 1) H2 Blockers: These drugs block the effect of histamine on H2 receptors which is present normally in gastric mucosa, vascular smooth muscle & the heart. They reduce the basal, food stimulated & nocturnal secretion of gastric HCl. Usually effective in controlling symptoms of mild to moderate GER & heal esophagitis (grade I,II) within 12 weeks in about ½ to 2/3 of patients.
  • 54. Drug Indication Dose Duration Cimetidine - Erosive esophagitis diagnosed by endoscopy. - 800 mg BDS or 400 mg QDS - 12 w Famotidine - Short term ttt of symptoms. - Esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy - 20 mg BDS - 20-40 mg BDS -6 w - 12 w Nizatidine - Esophagitis due to GERD. including erosive or ulcerative disease & associated heartburn. - 150 mg BDS - 12 w Ranitidine - Treatment of symptoms. - Esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy -150 mg BDS - 150 mg QDS No limit specifi ed
  • 55. 2) Proton Pump Inhibitors (PPIs): These drugs inhibit parietal cell proton pump (H+ K+ - ATPase). Proton pump is responsible for extrusion of H+ into the gastric lumen in exchange of K+ which is the final step in gastric acid production. PPIs are effective in control of symptoms & signs of GERD, heal erosive esophagitis & diminish formation of esophageal strictures. PPIs improves dysphagia & decrease the need for esophageal dilatation in patients who have esophageal strictures.
  • 56. PPIs are effective if taken 15-30 minutes before breakfast or dinner. Drugs of this group include: - Omeprazole 20 mg - 40 mg. - Lansoprazole 15 mg – 30 mg. - Rapeprazole 20 mg. - Pantoprazole 20 mg – 40 mg. - Esomeprazole 20 mg – 40 mg. - Omeprazole NaHCO3 20 mg – 40 mg.
  • 57. Side effects of PPIs: - Headache, nausea & vomiting. - Diarrhoea & Clostridium difficile colitis. - Theoretically, they may cause gastric bacterial overgrowth, vitamin B12 & iron malabsorption & gastric cancer. However, there is no clinical support. - Hypocalcaemia (give Ca++ supplements as Ca++ citrate).
  • 58. 3) Antacids: Antacids may be aluminum, magnesium, or calcium based Antacids neutralize the acid in the stomach so that there is no acid to reflux. Antacids emptied from the empty stomach quickly so they should be given an hour after meal to prolong their duration of action. Effective in controlling mild symptoms of GERD.
  • 59. 4) Prokinetic Drugs: These agents act by: a) Increasing LES pressure. b) Enhancing gastric & esophageal emptying. Examples: 1) Metoclopramide HCl. 2) Domperidone. 3) Mosapride citrate.
  • 60. 1) Metoclopramide HCl: - Dopamine antagonist, centrally acting antiemetic. - Its effective in treatment of mild disease. - It crosses BBB so, it has many central side effects. Side effects: Agitation, restlessness, somnolence, anxiety, insomnia, extrapyramidal manifestations & galactorrhoea.
  • 61. 2) Domperidone: - Dopamine antagonist & produce effects similar to metoclopramide. - Unlike metoclopramide it doesn’t cross BBB so there is no central side effects.
  • 62. 3) Mosapride citrate: - 5-HT4 receptor agonist & partial 5-HT3 antagonist. - Unlike cisapride it doesn’t block K+ channels so no cardiac toxicity will occur, also doesn’t block D2 receptors, so there is no extrapyramidal manifestations.
  • 63. 5) Sucralfate: - An aluminum sucrose polysulfate. - Effective in treatment of mild reflux esophagitis. - It is efficacy is comparable to that of H2 blockers.
  • 64. B) Antireflux Surgery: There are a number of different antireflux operations (e.g. Nissen, Belesy, Toupet fundoplication). The most popular is Nissen fundoplication (open or laparoscopic). Nissen fundoplication
  • 65. Principle of antireflux surgery: The surgeon 1) Creates an intraabdominal segment of esophagus. 2) Reduces the hiatal hernia. 3) Approximates the diaphragmatic crurae. 4) Wraps a portion of gastric fundus around the distal esophagus.
  • 66. - There is relief of symptoms & signs in > 85% of patients. - Antireflux surgery was associated with a significant decrease in long term survival so it should be restricted to: 1) Patients who no longer need to take antisecretory medications. 2) The procedure will prevent esophageal cancer
  • 67. C) Endoscopic Antireflux Procedures: The Bard endoscopic suturing system: This system uses an endoscopic sewing machine device to plicate the esophagogastric junction from the mucosal side. The Stretta system: The Stretta system delivers radiofrequency energy that creates thermal lesions in the LES muscle. Injection of collagen circumferentially at the LES.
  • 69. 1) Esophageal Stricture: Peptic strictures form when reflux induced ulceration stimulates fibrous tissue production & collagen deposition in the esophagus. Up to 11% of patients with GERD seem to develop strictures.
  • 70. Factors predisposing to stricture formation: - Prolonged GER. - Reflux while supine. - Nasogastric intubation. - Duodenal ulcer disease. - Gastric hypersecretory states. - Postgastrectomy states. - Scleroderma. - Treated achalasia.
  • 71. Site of esophageal stricture: - Usually in the distal 1/3 of the esophagus. - In some cases of Barrett’s esophagus the stricture is located in the middle or less commonly in the proximal 1/3 of the esophagus.
  • 72. Clinical Picture: - Esophageal stricture produce no symptoms until the esophageal intraluminal diameter < 12 mm. - Typically there is a slowly progressive dysphagia initially for solids & later on for liquids. - Profound weight loss is uncommon.
  • 73. Investigations: a)Barium Swallow: - Peptic strictures have a smooth tapered appearance. - More sensitive than endoscopy for demonstrating subtle esophageal narrowing. b) Endoscopy: - Endoscopic examination with biopsy & brush cytology of the esophagus is necessary to exclude cancer.
  • 74. Treatment: - Intensive medical treatment with PPIs both improves dysphagia & decreases the need for esophageal dilatation. - Progressive dilatation with: • Mercury filled rubber bougies. • Savary-Gillard dilators. • Balloons that can be inflated within the stricture.
  • 75. - Surgical treatment, usually combined with an antireflux operation. - Resection with esophageal reconstruction using a segment of bowel in cases of intractable stricture.
  • 76. B) Barrett’s Esophagus: - A condition in which a metaplastic columnar epithelium replaces squamous epithelium in the distal esophagus. - Barrett’s esophagus is a strong risk factor for adenocarcinoma of the esophagus & gastroesophageal junction.
  • 77. - It is usually discovered in middle aged & older adults. However its found in children as young as 5 years. - Barrett’s esophagus predominates in white males. Its uncommon in blacks & asians.
  • 78. Histology: Any of 3 types of columnar epithelia can be found in Barrett’s esophagus. 1) Gastric fundic type epithelium. 2) Junctional type epithelium. 3) Specialized intestinal metaplasia “Specialized columnar epithelium”. - Dysplasia & carcinoma are associated with intestinal metaplasia.
  • 79. Diagnosis Clinical Picture: - The Barrett’s epithelium causes no symptoms. - Most patients have symptoms of GERD, the GERD associated with Barrett’s esophagus often is severe & associated with esophageal ulceration, stricture & haemorrhage. However, many patients have no symptoms of GERD. - Cancer risk is about 0.5% annually.
  • 80. Endoscopy: - Columnar epithelium can be recognized by it’s characteristic red colour & velvet like texture that contrast sharply with the pale glossy appearance of the adjacent squamous epithelium. - According to the length of the lining columnar epithelium Barrett’s esophagus can be classified into: - Short segment Barrett’s esophagus: intestinal metaplasia lines < 3 cm of the distal esophagus.
  • 81. - Long segment Barrett’s esophagus: intestinal metaplasia lines > 3 cm of the distal esophagus. - Long segment Barrett’s esophagus is associated with high risk for developing adenocarcinoma.
  • 82. Management • Patients with Barrett’s esophagus should undergo surveillance endoscopy & biopsy at an interval determined by the presence & grade of dysplasia: • For patients with no dysplasia, surveillance endoscopy is recommended at an interval of every 2-3 years.
  • 83. • For patients with low grade dysplasia, surveillance endoscopy every 6 months for the 1st year is recommended, followed by yearly endoscopy if the dysplasia hasn’t progressed in severity. • For patients with high grade dysplasia 2 options are available: 1) Intensive endoscopic surveillance until intramucosal cancer is detected. 2) Esophageal resection.
  • 84. - GERD should be treated aggressively prior to surveillance endoscopy to minimize confusion caused by inflammation in the interpretation of biopsy specimens.
  • 86. Refractory GERD: patients who continue to have symptoms of gastroesophageal reflux despite standard treatment with proton pump inhibitors (PPIs). Patients who experience refractory GERD usually fall into one of two groups: - Those who need more aggressive treatment - Those who have other causes of their reflux symptoms
  • 88. Factors contributing to inadequate PPI response: 1) Nocturnal Acid Breakthrough (NAB) 2) Reduced bioavailability 3) Effect of food and dosing interval 4) Differences in metabolism 5) Gastric acid hypersecretion 6) Helicobacter pylori status 7) Drug resistance, slow healing
  • 89. Nocturnal Acid Breakthrough (NAB) Nocturnal acid exposure while on PPI. Responsible for majority of patients with refractory GERD. May be reduced by H2 blockers and by increasing PPI dose. Sometimes difficult to eliminate.
  • 90. Reduced Bioavailability Bioavailability of PPI influenced by environmental and manufacturing conditions. For most patients, difference in bioavailability are not clinically significant.
  • 91. Effect of food and dosing interval Administration 15-30 min prior to meals improve gastric acid suppression. PPI usually given once daily and sometimes twice daily improve gastric acid suppression.
  • 92. Differences in metabolism PPI metabolized through the CYP 2C. CYP 2C absent: - 3% of Caucasian patients. - In more than 10% in Asians.
  • 93. Gastric acid hypersecretion Patients with BAO > 10mEq/h may predisposed to refractory GERD.
  • 94. Helicobacter pylori status Role not established in refractory patients. Helicobacter pylori infection may protect the esophagus from GERD & its complications perhaps by decreasing gastric acidity. No evidence that eradication exacerbates GERD.
  • 95. Drug Resistance Resistance is a rare condition caused by mutations of the proton pump. Patients can be treated by H2 blockers.
  • 96. 2) Other causes of reflux symptoms
  • 97. Other Causes Of Reflux Symptoms: 1) Other pathological situations. 2) Esophageal hypersensitivity. 3) Non acid reflux.
  • 98. Other Pathological Situation 1) IBS and dyspepsia with overlap syndrome. 2) Atypical GERD (cough, asthma, NCCP). 3) Achalasia. 4) Cancer or stricture. 5) Caustic and Infectious esophagitis. 6) NSAID (more susceptibility to acid related E disease).
  • 99. Esophageal Hypersensitivity There is hypersensitivity to physiologic acid reflux (visceral hyperalgesia). Patients have heartburn but without endoscopic or pH evidence of GERD. Treatment: Acid suppressive therapy and low dose antidepressants
  • 100. Non Acid Reflux Mixed acid and bile refluxate (more aggressive than acid alone). Duodenogastroesophageal reflux (DGER): in patients with gastric surgery.
  • 102. Medical treatment -Give PPI twice daily. -PPI dose before dinner may reduce NAB. -PPI 15-30 min before meals. - Stepwise increase dose of PPI to achieve adequate acid suppression (an increase in dose of Omeprazole to 80 mg/ day→ significant decrease in acid secretion (Vs 20 mg bid) (pH <4: 33% Vs 74%).
  • 103. - Addition of a nighttime dose H2 blockers to control NAB. - H2 blockers not as effective as PPI for maintenance therapy. - Switching to another PPI for patients refractory to one PPI ( rare mutations in the PP induce resistance). - Effectiveness of adding prokinetic drug not established.
  • 104. - Add Baclofen (GABA-B agonist ): • Effective to treat GERD with chronic cough. • Inhibits TLESR. • With Esomeprazole both decrease total acid and non acid reflux. Endoscopic treatment Surgical treatment